NASDAQ:PRAH - PRA Health Sciences Stock Price, Price Target & More

Get Started

$81.11 +0.22 (+0.27 %)

(As of 05/27/2018 06:05 AM ET)

Previous Close$81.11

Today's Range$80.28 - $81.4397

52-Week Range$69.57 - $95.90

Volume228,071 shs

Average Volume395,912 shs

Market Capitalization$5.18 billion

P/E Ratio24.81

Dividend YieldN/A

Beta0.5

About PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:PRAH

CUSIPN/A

Webwww.prahs.com

Phone919-786-8200

Debt

Debt-to-Equity Ratio1.29

Current Ratio0.83

Quick Ratio0.83

Price-To-Earnings

Trailing P/E Ratio24.81

Forward P/E Ratio21.29

P/E Growth1.25

Sales & Book Value

Annual Sales$2.26 billion

Price / Sales2.30

Cash Flow$4.7075 per share

Price / Cash17.23

Book Value$14.75 per share

Price / Book5.50

Profitability

EPS (Most Recent Fiscal Year)$3.20

Net Income$86.92 million

Net Margins4.07%

Return on Equity23.06%

Return on Assets6.84%

Miscellaneous

Employees15,800

Outstanding Shares64,080,000

PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences (NASDAQ:PRAH) released its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.01. The medical research company had revenue of $701.80 million for the quarter, compared to analyst estimates of $694.73 million. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. PRA Health Sciences's revenue was up 43.9% compared to the same quarter last year. During the same period last year, the firm posted $0.62 earnings per share. View PRA Health Sciences' Earnings History.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PRA Health Sciences.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

What price target have analysts set for PRAH?

11 brokerages have issued twelve-month price objectives for PRA Health Sciences' shares. Their predictions range from $86.00 to $104.00. On average, they anticipate PRA Health Sciences' stock price to reach $95.1818 in the next twelve months. View Analyst Ratings for PRA Health Sciences.

Who are some of PRA Health Sciences' key competitors?

Some companies that are related to PRA Health Sciences include Incyte (INCY), Icon (ICLR), EXACT Sciences (EXAS), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX) and Viralytics (VRACY).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the folowing people:

Mr. Colin Shannon, Chairman, CEO & Pres (Age 59)
Ms. Linda Baddour, Exec. VP, CFO, Corp. Sec. & Principal Accounting Officer (Age 60)
Dr. David W. Dockhorn, Exec. VP & Corp. Compliance Officer (Age 57)
Michael J. Bonello, Sr. VP of Accounting and Corp. Controller
Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Has PRA Health Sciences been receiving favorable news coverage?

Media headlines about PRAH stock have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PRA Health Sciences earned a media sentiment score of 0.14 on Accern's scale. They also gave news stories about the medical research company an impact score of 45.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.66%), Eagle Asset Management Inc. (1.92%), Wells Fargo & Company MN (1.64%), Northern Trust Corp (0.97%), Vaughan Nelson Investment Management L.P. (0.80%) and OppenheimerFunds Inc. (0.79%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Federated Investors Inc. PA, Hood River Capital Management LLC, BlackRock Inc., Rock Springs Capital Management LP, American Century Companies Inc. and King Luther Capital Management Corp. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Clinton Group Inc., Stephens Investment Management Group LLC, OppenheimerFunds Inc., Prudential Financial Inc. and California Public Employees Retirement System. View Insider Buying and Selling for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $81.11.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $5.18 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]

MarketBeat Community Rating for PRA Health Sciences (PRAH)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		221 (Vote Outperform)
Underperform Votes:		186 (Vote Underperform)
Total Votes:		407

MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.

PRA Health Sciences (NASDAQ:PRAH) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

11 Wall Street analysts have issued ratings and price targets for PRA Health Sciences in the last 12 months. Their average twelve-month price target is $95.1818, suggesting that the stock has a possible upside of 17.35%. The high price target for PRAH is $104.00 and the low price target for PRAH is $86.00. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.91	2.91	2.83	2.90
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$95.1818	$95.1818	$92.50	$88.60
Price Target Upside:	17.35% upside	6.96% upside	3.94% upside	8.00% upside

PRA Health Sciences (NASDAQ:PRAH) Consensus Price Target History

Price Target History for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ:PRAH) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/22/2018	Credit Suisse Group	Reiterated Rating	Outperform ➝ Outperform	$101.00 ➝ $104.00	High
1/31/2018	KeyCorp	Reiterated Rating	Buy	$100.00	Low
1/24/2018	Mizuho	Downgrade	Buy ➝ Neutral	$86.00	High
12/15/2017	Mitsubishi UFJ Financial Group	Initiated Coverage	Overweight	$102.00	Low
12/11/2017	Barclays	Initiated Coverage	Overweight ➝ Overweight	$94.00	Medium
12/1/2017	Robert W. Baird	Set Price Target	Buy	$94.00	Low
10/27/2017	SunTrust Banks	Reiterated Rating	Buy	$101.00	N/A
10/26/2017	Jefferies Group	Reiterated Rating	Buy	$95.00	N/A
8/16/2017	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$89.00	Low
8/10/2017	Citigroup	Reiterated Rating	Buy	$90.00 ➝ $93.00	Low
6/26/2017	Bank of America	Initiated Coverage	Buy	$89.00	Low
2/27/2017	Avondale Partners	Upgrade	Underperform ➝ Market Perform	$63.00	N/A
9/6/2016	UBS	Downgrade	Buy ➝ Neutral	$50.00 ➝ $55.00	N/A
6/20/2016	First Analysis	Initiated Coverage	Equal ➝ Equal Weight	$47.00	N/A

(Data available from 5/27/2016 forward)

PRA Health Sciences (NASDAQ:PRAH) Earnings History and Estimates Chart

Earnings by Quarter for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ:PRAH) Earnings Estimates

2018 EPS Consensus Estimate: $3.91

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.76	$0.76	$0.76
Q2 2018	2	$0.91	$0.92	$0.92
Q3 2018	2	$0.99	$1.05	$1.02
Q4 2018	2	$1.17	$1.25	$1.21

PRA Health Sciences (NASDAQ PRAH) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		$0.96					N/A
4/25/2018	Q1 2018	$0.84	$0.85	$694.73 million	$701.80 million	View	N/A
2/21/2018	Q4 2017	$1.02	$1.04	$543.78 million	$568.80 million	View	N/A
10/25/2017	Q3 2017	$0.85	$0.88	$477.89 million	$494.55 million	View	N/A
8/7/2017	Q2 2017	$0.72	$0.62	$447.79 million	$457.90 million	View	Listen
4/25/2017	Q1 2017	$0.58	$0.60	$426.81 million	$427.08 million	View	N/A
2/22/2017	Q4 2016	$0.64	$0.71	$405.04 million	$413.61 million	View	N/A
11/2/2016	Q316	$0.64	$0.64	$394.87 million	$399.80 million	View	N/A
7/28/2016	Q2	$0.59	$0.63	$381.25 million	$394.20 million	View	Listen
4/27/2016	Q116	$0.53	$0.55	$372.21 million	$372.30 million	View	Listen
2/24/2016	Q4	$0.49	$0.59	$353.42 million	$428.90 million	View	Listen
11/2/2015	Q3	$0.45	$0.52	$346.05 million	$345.10 million	View	Listen
7/27/2015	Q215	$0.40	$0.47	$336.74 million	$336.50 million	View	Listen
5/6/2015	Q115	$0.31	$0.41	$329.80 million	$332.00 million	View	Listen
2/18/2015	Q414	$0.30	$0.35	$323.50 million	$370.00 million	View	Listen

(Earnings results data provided by Zacks Investment Research)

PRA Health Sciences (NASDAQ:PRAH) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

PRA Health Sciences (NASDAQ PRAH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.85%
Institutional Ownership Percentage: 99.24%

Insider Trading History for PRA Health Sciences (NASDAQ:PRAH)

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences (NASDAQ PRAH) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2018	Linda Baddour	VP	Sell	67,000	$90.27	$6,048,090.00
12/28/2017	David W Dockhorn	Insider	Sell	72,850	$90.83	$6,616,965.50
12/28/2017	David W Dockhorn	EVP	Sell	72,850	$90.83	$6,616,965.50	72,850
11/16/2017	Matthew P Young	Director	Sell	5,115	$79.90	$408,688.50
8/14/2017	Colin Shannon	CEO	Sell	400,000	$74.85	$29,940,000.00
8/14/2017	Linda Baddour	VP	Sell	100,000	$74.85	$7,485,000.00
8/14/2017	Pra Investors L.P. Kkr	Major Shareholder	Sell	9,500,000	$74.85	$711,075,000.00
4/17/2017	Linda Baddour	VP	Sell	196,393	$63.59	$12,488,630.87	124,472
3/28/2017	Colin Shannon	CEO	Sell	50,000	$64.00	$3,200,000.00	50,000
3/27/2017	David W Dockhorn	Insider	Sell	85,182	$62.00	$5,281,284.00	55,574
2/23/2017	Colin Shannon	CEO	Sell	100,000	$61.50	$6,150,000.00	2,747
8/22/2016	Colin Shannon	CEO	Sell	113,133	$51.57	$5,834,268.81	120,000
8/15/2016	Linda Baddour	VP	Sell	69,380	$52.00	$3,607,760.00	69,380
8/12/2016	David W. Dockhorn	VP	Sell	107,257	$49.00	$5,255,593.00
5/6/2016	Linda Baddour	CFO	Sell	92,308	$46.70	$4,310,783.60
5/6/2016	Pra Investors L.P. Kkr	Major Shareholder	Sell	4,907,692	$46.70	$229,189,216.40
3/8/2016	Colin Shannon	CEO	Sell	77,019	$42.26	$3,254,822.94
3/8/2016	Linda Baddour	CFO	Sell	93,000	$42.26	$3,930,180.00
3/8/2016	Pra Investors L.P. Kkr	Major Shareholder	Sell	4,829,981	$42.26	$204,114,997.06

(Data available from 1/1/2013 forward)

PRA Health Sciences (NASDAQ PRAH) News Headlines

Source:

Date	Headline
	PRA Named International Clinical Research Company of the Year finance.yahoo.com - May 24 at 9:03 AM
	$678.55 Million in Sales Expected for PRA Health Sciences (PRAH) This Quarter www.americanbankingnews.com - May 19 at 3:56 AM
	ICON (ICLR) versus PRA Health Sciences (PRAH) Head to Head Review www.americanbankingnews.com - May 18 at 5:27 AM
	Head to Head Contrast: PRA Health Sciences (PRAH) and Luna Innovations (LUNA) www.americanbankingnews.com - May 17 at 7:40 PM
	$0.94 Earnings Per Share Expected for PRA Health Sciences (PRAH) This Quarter www.americanbankingnews.com - May 17 at 2:27 PM
	IQVIA Has Fallen 2.9%, but Analysts Are Still on Board finance.yahoo.com - May 17 at 9:18 AM
	Financial Review: Luna Innovations (LUNA) versus PRA Health Sciences (PRAH) www.americanbankingnews.com - May 17 at 1:25 AM
	PRA Health Sciences (PRAH) Downgraded to "Hold" at ValuEngine www.americanbankingnews.com - May 7 at 10:36 PM
	PRA Health Sciences (PRAH) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - May 7 at 1:49 PM
	Critical Survey: BTG (BTGGF) versus PRA Health Sciences (PRAH) www.americanbankingnews.com - May 6 at 7:41 PM
	PRA Named Clinical Research Company of the Year and Makes the Forbes 2018 America’s Best Large Employers List finance.yahoo.com - May 3 at 4:42 PM
	PRA Health Sciences (PRAH) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - May 1 at 9:12 AM
	Edited Transcript of PRAH earnings conference call or presentation 26-Apr-18 1:00pm GMT finance.yahoo.com - May 1 at 9:09 AM
	PRA Health Sciences (PRAH) Expected to Announce Quarterly Sales of $712.99 Million www.americanbankingnews.com - May 1 at 1:46 AM
	Contrasting PRA Health Sciences (PRAH) and IQVIA (IQV) www.americanbankingnews.com - April 30 at 3:20 PM
	Zacks: Brokerages Anticipate PRA Health Sciences (PRAH) to Announce $0.95 Earnings Per Share www.americanbankingnews.com - April 29 at 9:06 PM
	PRA Health Sciences (PRAH) Downgraded to "Buy" at BidaskClub www.americanbankingnews.com - April 27 at 9:55 AM
	BRIEF-Pra Health Sciences Says CFO Linda Baddour To Retire www.reuters.com - April 27 at 9:35 AM
	PRA Health Sciences' (PRAH) CEO Colin Shannon on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - April 26 at 4:43 PM
	PRA’s longtime CFO to retire finance.yahoo.com - April 26 at 4:43 PM
	PRA Health Sciences (PRAH) Announces Retirement of CFO and Promotion of Michael Bonello to CFO www.streetinsider.com - April 26 at 8:57 AM
	PRA Health Sciences (PRAH) Announces Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - April 25 at 9:38 PM
	PRA Health Sciences (PRAH) Releases FY18 Earnings Guidance www.americanbankingnews.com - April 25 at 6:28 PM
	BRIEF-PRA Health Sciences Q1 GAAP Earnings Per Share $0.59 www.reuters.com - April 25 at 4:52 PM
	PRA Health Sciences: 1Q Earnings Snapshot finance.yahoo.com - April 25 at 4:52 PM
	PRA Health Sciences Announces Retirement of Chief Financial Officer and Promotion of Michael Bonello to CFO finance.yahoo.com - April 25 at 4:52 PM
	PRA Health Sciences, Inc. Reports First Quarter 2018 Results finance.yahoo.com - April 25 at 4:52 PM
	PRA Health Sciences (PRAH) Set to Announce Quarterly Earnings on Monday www.americanbankingnews.com - April 16 at 3:46 AM
	PRA Health Sciences (PRAH) Downgraded by BidaskClub www.americanbankingnews.com - April 14 at 9:51 PM
	PRA Health Sciences (PRAH) Expected to Post Quarterly Sales of $695.69 Million www.americanbankingnews.com - April 14 at 1:47 AM
	Zacks: Analysts Anticipate PRA Health Sciences (PRAH) Will Post Earnings of $0.84 Per Share www.americanbankingnews.com - April 12 at 11:14 PM
	PRA Health Sciences (PRAH) PT Raised to $83.00 www.americanbankingnews.com - April 12 at 8:29 PM
	PRA Health Sciences to Report First Quarter 2018 Earnings finance.yahoo.com - April 12 at 4:48 PM
	PRA Health Sciences (PRAH) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - April 12 at 1:41 PM
	SunTrust Banks Reaffirms Buy Rating for PRA Health Sciences (PRAH) www.americanbankingnews.com - April 11 at 11:23 PM
	PRA Health Sciences (PRAH) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 9 at 9:12 PM
	PRA Health Sciences (PRAH) Stock Rating Reaffirmed by KeyCorp www.americanbankingnews.com - April 4 at 2:26 PM
	Q4 2018 Earnings Forecast for PRA Health Sciences (PRAH) Issued By First Analysis www.americanbankingnews.com - April 4 at 6:44 AM
	Using Social Media To Accelerate Drug Development: 'The Only Way To Change The Paradigm' finance.yahoo.com - April 3 at 9:22 AM
	PRA Health Sciences (PRAH) and Cleveland BioLabs (CBLI) Head-To-Head Contrast www.americanbankingnews.com - April 2 at 7:16 PM
	Head to Head Analysis: PRA Health Sciences (PRAH) versus BioM�rieux (BMXMF) www.americanbankingnews.com - March 31 at 1:26 PM
	PRA Health Sciences (PRAH) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - March 31 at 12:49 PM
	PRA Health Sciences (PRAH) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - March 30 at 3:58 PM
	Zacks Investment Research Downgrades PRA Health Sciences (PRAH) to Hold www.americanbankingnews.com - March 29 at 5:48 PM
	PRA Health Sciences (PRAH) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - March 28 at 9:48 PM
	PRA Health Sciences (PRAH) Expected to Post Quarterly Sales of $695.73 Million www.americanbankingnews.com - March 28 at 1:56 AM
	PRA Health Sciences (PRAH) Upgraded to "Strong-Buy" by BidaskClub www.americanbankingnews.com - March 26 at 11:30 PM
	PRA Health Sciences (PRAH) Cut to Sell at Zacks Investment Research www.americanbankingnews.com - March 24 at 2:45 PM
	PRA Health Sciences (PRAH) Upgraded to Strong-Buy at BidaskClub www.americanbankingnews.com - March 18 at 4:58 PM
	PRA Health Sciences Inc (PRAH) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - March 18 at 1:48 PM

PRA Health Sciences (NASDAQ:PRAH) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

PRA Health Sciences (NASDAQ:PRAH) Income Statement, Balance Sheet and Cash Flow Statement

PRA Health Sciences (NASDAQ PRAH) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff